Maryland caps Ozempic price for government insurers beginning in 2027

Maryland regulators moved to cap the cost of diabetes and weight-loss drug Ozempic on Monday, after taking similar action on Jardiance in April.

The move limits the cost paid for Ozempic to $274 per month for local government insurers, based on the Medicare Fair Price negotiated by the federal government insurer. That amount will be adjusted for inflation beginning in 2028, but it does not limit patient out-of-pocket costs set by either public sector or private, employer-provided insurance...

Read more at the Baltimore Sun.